Results 41 to 50 of about 212,261 (301)

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells

Oncotarget, 2017
Programmed cell death ligand 1 (PD-L1) is a transmembrane protein that is expressed on tumor cells that suppresses the T cell-mediated immune response. Therapies targeting the PD-L1 pathway promote anti-tumor immunity and have shown promising results in some types of cancers. However, the functional and therapeutic roles of PD-L1 in osteosarcoma remain
Liao, Yunfei, Chen, Lulu, Feng, Yong, Shen, Jacson, Gao, Yan, Duan, Zhenfeng, Cote, Gregory, Choy, Edwin, Harmon, David, Mankin, Henry, Hornicek, Francis   +10 more
openaire   +5 more sources

Protective effects of blocking PD-1 pathway on retinal ganglion cells in a mouse model of chronic ocular hypertension

Frontiers in Immunology, 2023
PurposeIn this study, we aimed to investigate whether Programmed cell death 1 ligand 1/programmed cell death 1 ligand 2 (PD-L1/PD-L2) double knockout (dKO) has a protective effect on RGCs in a mouse model of chronic ocular hypertension (COHT).MethodsWe ...
Siqi Sheng, Siqi Sheng, Siqi Sheng, Siqi Sheng, Yixian Ma, Yixian Ma, Yixian Ma, Yixian Ma, Yue Zou, Yue Zou, Yue Zou, Yue Zou, Fangyuan Hu, Fangyuan Hu, Fangyuan Hu, Fangyuan Hu, Ling Chen, Ling Chen, Ling Chen, Ling Chen   +19 more
doaj   +1 more source

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors

Medicine, 2021
Abstract Background: The method to evaluate the efficacy of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors has become a big concern for researchers with its widely application. Pseudoprogressive disease (PPD) makes this process more difficult, which means that the tumor progressed at ...
Jingyi Zhang, Kexin Tan, Xuejiao Jiang, Shuyue Zheng, Jia Li, Chongxiang Xue, Xu Zhang, Huijuan Cui   +7 more
openaire   +2 more sources

Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]

, 2016
BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas, Chmielowski, Bartosz, Crompton, Joseph G, Dry, Sarah, Eilber, Fritz C, Federman, Noah, Jensen, Sarah, Li, Yunfeng, Nelson, Scott, Shurell, Elizabeth, Singh, Arun S, Tumeh, Paul   +11 more
core   +2 more sources

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis

Tzu Chi Medical Journal, 2023
Objectives: This study aimed to investigate the efficacy and safety of programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in patients with advanced hepatocellular carcinoma (HCC).
Tzu-Rong Peng, Li-Jou Yang, Ta-Wei Wu
doaj   +1 more source

D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER

Pakistan Armed Forces Medical Journal, 2021
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer cases and its correlation with clinicopathological factors. Study Design: Cross sectional study. Place and Duration of Study: Histopathology department,
Sammeen Salim, Muhammad Asif, Rabia Ahmed, Muhammad Tahir Khadim   +3 more
doaj   +1 more source

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab [PDF]

, 2016
Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration.
Caponnetto, Salvatore, Cortesi, Enrico, DEL BENE, Gabriella, Gandini, Orietta, Gazzaniga, Paola, Gradilone, Angela, Longo, F, Mancini, Marialaura, Mastromartino, M, Nicolazzo, Chiara, Prete, ALESSANDRA ANNA, Raimondi, Cristina   +11 more
core   +1 more source

Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells [PDF]

, 2012
For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner.
Barna, Gabor, Bauer, Pal I., Dunai, Zsuzsanna A., Imre, Gergely, Korcsmaros, Tamas, Mihalik, Rudolf, Petak, Istvan   +6 more
core   +3 more sources

Autophagy controls programmed death‑ligand 1 expression on cancer cells (Review)

Biomedical Reports, 2021
Programmed death-ligand 1 (PD-L1) is a transmembrane protein mainly located on cancer cells, including renal cell carcinoma, breast, colorectal, gastric and non-small cell lung cancer. PD-L1 binds to the PD-1 receptor expressed on T lymphocytes to inhibit the activation of T lymphocytes, thus allowing tumour cells to escape immune surveillance, leading
Lijuan, Gao, Yongshun, Chen
openaire   +3 more sources

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer

Therapeutic Advances in Medical Oncology, 2020
Background: The introduction of antibodies targeting programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) into clinical practice has had a revolutionary effect on cancer treatment.
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj   +1 more source